Key result
Vaccination with a mixed live infectious bronchitis vaccine significantly reduced viral shedding and resulted in lower morbidity (15% vs 100%) and mortality (0% vs 100%) compared to non-vaccinated controls after virulent challenge.
Why the study?
Does a mixed live vaccine reduce viral shedding and improve protection against virulent infectious bronchitis virus challenge in broiler chickens?
RCT (n=250)
Randomly divided into five groups
No
Does a mixed live vaccine reduce viral shedding and improve protection against virulent infectious bronchitis virus challenge in broiler chickens?
Absolute Event Rate: 15% vs 100%
p-value: p=<0.05
A mixed live vaccine protocol provides superior protection and reduces viral shedding against virulent infectious bronchitis virus challenge in broiler chickens compared to single-strain vaccines.
May support mixed IBV vaccination in broilers; leaves open field efficacy and commercial translation.
Infectious bronchitis threatens the poultry industry throughout the world, The control of IB of the big problems in the world because of the wide variations in serotypes and development in the virulence of strains from time to time, and nature is very contagious, the rapid evolution in the specific tissue tropism and recombinants because of the synchronization of infection with different virus types and the use of live vaccines.found that the IB virus which is isolated from the recent outbreak is the same serotype but the difference genotype compared with the strains of current vaccine. Previous studies have indicated that the broiler vaccination with inactivated vaccines showed significantly less virus shed if challenge with the homologous vaccines (same genotype viruses) as compared with birds that vaccination genetically heterologous vaccines. The current study compared the extent of protection resulting from vaccination with live Commercial vaccines(Volvac® IB Mass MLV, Poulvac® IB Primer (D274), Avipro® IB M48 and mixed vaccine from (Volvac®, Poulvac® and Avipro®)). Vaccinates werechallenged with virulent field isolate (Variant2) strain. Weekly post-vaccination, collected serum for analytical knowledge of the amount of antibodies using hemagglutiation inhibition test against all vaccine antigens used in the experiment after challenge with field virulent (Variant2 isolate), examine the birds daily to monitor the morbidity and mortality rates in selected periods for shedding virus by real time PCRto detect and quantitate the IBV viral copy number from clinical samples.After challenge with (Variant2) birdsvaccinated with mixed vaccine revealed less shedding virus compared to (Volvac®, Poulvac® and Avipro®)- vaccinated birdsboth separately.Genotypic differences between the vaccines and the challenge virus do not reduce the ability of vaccines to protect against the disease, but genotypic similarities reduce the virus shed and limiting its spread. The use of same249 genetically advanced vaccines and expected to provide the best protection against the challenge with virulent field IB strains and limit the spread of poultry farming
No takes yet. Share an insight, caveat, or question.
Sahar Hamdi Abdulmaged (2017) conducted an RCT in Infectious bronchitis (n=250). Mixed live commercial vaccines (Volvac, Poulvac, Avipro) vs. Non-vaccinated control and single vaccine groups was evaluated on Morbidity rate post-challenge (p=<0.05). Vaccination with a mixed live infectious bronchitis vaccine significantly reduced viral shedding and resulted in lower morbidity (15% vs 100%) and mortality (0% vs 100%) compared to non-vaccinated controls after virulent challenge.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: